Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
0 hedge funds and large institutions have $0 invested in Turning Point Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 208 closing their positions.
100% less funds holding
Funds holding: 208 → 0 (-208)
100% less funds holding in top 10
Funds holding in top 10: 10 → 0 (-10)
100% less capital invested
Capital invested by funds: $3.06B → $0 (-$3.06B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 208
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$313M |
| 2 |
BlackRock
New York
|
-$285M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$187M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$144M |
| 5 |
State Street
Boston,
Massachusetts
|
-$124M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AF
201
Allworth Financial
Folsom,
California
| – | -$1K | -18 | Closed |
|
202
Rockefeller Capital Management
New York
| – | -$1K | -15 | Closed |
|
|
PA
203
Parallel Advisors
San Francisco,
California
| – | -$1K | -10 | Closed |
|
|
CTC
204
Central Trust Company
Jefferson City,
Missouri
| – | -$1K | -7 | Closed |
|
|
C
205
Covestor
London,
United Kingdom
| – | -$1K | -6 | Closed |
|
TPTX Hedge Fund Activity: Q3 2022 in Review
0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2022, worth a combined $0 — down 100% from $3.06B a quarter earlier.
Sellers outnumbered buyers: 208 funds closed out of TPTX and 0 opened new positions — a net loss of 208 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $313M sold.
- 0 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2022, down from 208 in Q2 2022.
- Funds reported $0 of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
- 0 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2022 and 208 closed out, a net change of -208 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $313M sold.
Based on aggregated 13F filings for Q3 2022.